1 completed, 1 terminated. 2 Phase 3.
| Phase | Trials | Status |
|---|---|---|
| Phase 3 | 2 | Completed 1, Terminated 1 |
Follow lufotrelvir: new trials by email Literature Review of lufotrelvir trials Research Report on lufotrelvir
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| PF-07304814 for Inpatients With COVID-19 (An ACTIV-3/TICO Treatment Trial) PF-07304814, Placebo, Remdesivir - COVID-19 | Phase 3 | Terminated | National Institute of Allergy and Infectious Diseases (NIAID) | 58 | 2021-09-15 | 2024-02-09 |
| ACTIV-3: Therapeutics for Inpatients With COVID-19 LY3819253, Placebo, Remdesivir - Covid19 | Phase 3 | Completed | National Institute of Allergy and Infectious Diseases (NIAID) | 2753 | 2020-08-04 | 2023-08-25 |
COVID-19 (2) · Coronaviridae Infections (2) · Coronavirus Infections (2) · Nidovirales Infections (2) · RNA Virus Infections (2) · Severe Acute Respiratory Syndrome (2) · Virus Diseases (2)
National Institute of Allergy and Infectious Diseases (NIAID) (2)
Denmark (2) · United States (2) · Greece (1) · Nigeria (1) · Poland (1) · Singapore (1) · Spain (1) · Switzerland (1) · Uganda (1) · United Kingdom (1)
James Neaton, Prof. (1) · Jens Lundgren, Prof. (1) · Prof. James Neaton (1) · Prof. Jens Lundgren (1)
PMID 33356051, PMID 34473343, PMID 34928698, PMID 34953520, PMID 35298440, PMID 35713300, PMID 35817072, PMID 35939810, PMID 37948759, PMID 39922466, PMID 40262279